Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
This is a research study involving the use of a contrast agent called Ultravist Injection.
Ultravist, the study drug, is used to improve the pictures obtained using computed
tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read.
In the case of this study, it will be injected into a vein in the patient's arm; from there,
it travels through the blood stream and to the areas to be examined. CT scans will then be
taken of the patient's head and/or body as ordered by his/her physician.
Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When
Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast
Enhanced Computed Tomography (CECT) of the Head and/or Body
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
The purpose of this study is to obtain data on the safety and efficacy of Ultravist
application in usual daily use.The radiologist will administer the contrast medium to the
patient as he/she would have done without the study. No other examinations will be performed
than would have been done routinely.
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
This study is to collect the information of Ultravist® in the patients indicated for the
coronary angiography or PCI, like rate of ADR in patients, the dose for different
indications, image quality to prove Ultravist the good safety and effectivity
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol
(Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide
(Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability
(quality and interpretability of images).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.